American Healthcare REIT

AHR · NYSE

$54.36−$0.44 (−0.80%)TodayMarket closed · Oct 21, 4:01 AM ET

Prev close $54.80

AHR analyst rating

BuyConsensus of 12 analysts over the last 12 months. 100% rate it a buy.

Strong buy1
Buy11
Hold0
Underperform0
Sell0

12-month price target · 16 analysts

Average $65.35 (+20.2% upside)

Low: $55.55
Now: $54.36
High: $77.70

Upgrades and downgrades

The latest rating actions, newest first

AHR analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
UBS	Oct 13, 2026	Maintains	Buy	$63.00 → $62.00	45%
Barclays	Oct 13, 2026	Maintains	Overweight	$66.00 → $60.00	38%
Raymond James	Oct 13, 2026	Initiates	Strong Buy	$62.00	53%
Scotiabank	Sep 2, 2026	Maintains	Sector Outperform	$56.00 → $62.00	47%
Barclays	Aug 31, 2026	Maintains	Overweight	$61.00 → $66.00	38%
Keybanc	Aug 19, 2026	Maintains	Overweight	$58.00 → $68.00	63%
Truist Securities	Aug 14, 2026	Maintains	Buy	$57.00 → $61.00	45%
RBC Capital	Aug 14, 2026	Maintains	Outperform	$56.00 → $61.00	58%
Citigroup	Aug 13, 2026	Maintains	Buy	$55.00 → $65.00	44%
Citizens	Jul 27, 2026	Maintains	Market Outperform	$60.00 → $65.00	40%

The case for and against

Updated Oct 15, 2026

Bull case

American Healthcare REIT is well positioned for durable fundamental outperformance because its core Integrated Senior Health Campuses business, which contributes about 60% of NOI, is still producing mid-teens growth and benefits from occupancy gains, higher-acuity mix, Q-mix, and value-based reimbursement. The SHOP platform adds another layer of upside, with occupancy of 88.8%, 19.5% midpoint 2026 SSNOI growth guidance, and a rising mix of private-pay, higher-acuity assets that should support pricing power and margin expansion as investments scale. Balance-sheet strength and accretive capital deployment further reinforce the outlook, as more than $2 billion of liquidity and over $2.4 billion of closed, awarded, or pipeline investments should drive meaningful nFFO growth while keeping leverage at a historically low 3.4x net debt to EBITDA.

Bear case

American Healthcare REIT is viewed negatively because its 4.7% implied cap rate sits well below the healthcare sector average of 6.1%-6.2% and the REIT average of 7.0%-7.3%, leaving little margin for operational disappointment. The outlook is further pressured by heavy concentration risk, since over half of NOI comes from Trilogy and roughly half of Trilogy NOI is tied to skilled nursing beds, exposing results to reimbursement cuts, Medicaid changes, and headline risk. Although NAV was raised to $31.71/sh and near-term SSNOI growth was solid, the company’s dependence on a volatile SNF operating environment, uncertain labor conditions, and potential cost-of-capital constraints supports a cautious fundamental view.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.